IgA Nephropathy Epidemiology Forecast 2025-2034

IgA nephropathy predominantly affects young adults, shows male predominance, and varies across ethnicities, with highest incidence in Asian/Pacific Islanders. Early diagnosis is crucial to prevent progressive kidney damage. As per IgA nephropathy epidemiology forecast by Expert Market Research, the prevalence is slightly higher in men as compared to women.

IgA Nephropathy Epidemiology Forecast Report Coverage

Expert Market Research's “IgA Nephropathy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of IgA nephropathy. It projects the future incidence and prevalence rates of IgA nephropathy cases across various populations. The study covers age, gender, and type as major determinants of the IgA nephropathy population. The report highlights patterns in the prevalence of IgA nephropathy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on IgA nephropathy epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

IgA Nephropathy Understanding: Disease Overview

IgA nephropathy (IgAN) is a chronic kidney disease characterized by the deposition of immunoglobulin A (IgA) in the glomerular mesangium, leading to inflammation and progressive renal damage. It is the most common primary glomerulonephritis worldwide, with peak onset in the second and third decades of life. Clinical manifestations include hematuria, proteinuria, hypertension, and, in advanced cases, chronic kidney disease or end-stage renal failure. Diagnosis relies on renal biopsy with immunofluorescence. Management focuses on blood pressure control, immunosuppressive therapy in select patients, and supportive measures to slow disease progression.

IgA Nephropathy Epidemiology Perspective

The IgA nephropathy epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the IgA nephropathy epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for IgA nephropathy and their trends. The IgA nephropathy detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• IgA nephropathy (IgAN) typically presents in late teens to early 30s, with many patients diagnosed during this period, highlighting its impact on young adults.
• In a study of 9,392 kidney biopsy patients, 606 adults were diagnosed with primary IgAN, demonstrating a significant prevalence within the adult population.
• Globally, IgAN shows male predominance, with a male-to-female ratio ranging from 1.5:1 to 2:1, indicating higher susceptibility among men across populations.

Country-wise IgA Nephropathy Epidemiology Segment

The IgA nephropathy epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, IgA nephropathy (IgAN) predominantly affects males, with a peak onset in late teens to early 30s. Incidence rates vary across ethnic groups, being highest among Asian/Pacific Islander populations (4.5 per 100,000 person-years), followed by Hispanic (1.7), White (1.2), and Black (0.6) populations. The condition is the most common primary glomerulonephritis in adults, often presenting with hematuria, proteinuria, and progressive renal dysfunction. Early diagnosis through renal biopsy and appropriate management is crucial to slow progression toward chronic kidney disease or end-stage renal failure.

IgA Nephropathy: Treatment Overview

The treatment strategies focus on slowing progression and managing proteinuria and hypertension. Standard care includes RAAS inhibitors, blood pressure control, and supportive therapies. Recently approved disease-modifying agents, including targeted-release corticosteroids (budesonide) and dual endothelin/angiotensin receptor blockers (sparsentan), aim to reduce proteinuria and delay progression to end-stage kidney disease. Immunosuppressants are used selectively in high-risk cases. Management also includes lifestyle modifications and monitoring kidney function regularly. Early intervention and individualized therapy, often coordinated by nephrologists, are essential to improve long-term renal outcomes and quality of life.

Key Questions Answered

• What are the key findings of IgA nephropathy epidemiology in the 8 major markets?
• What will be the total number of patients with IgA nephropathy across the 8 major markets during the forecast period?
• What was the country-wise IgA nephropathy epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of IgA nephropathy during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of IgA nephropathy during the forecast period of 2025-2034?
• What are the currently available treatments for IgA nephropathy ?
• What are the disease risks, signs, symptoms, and unmet needs of IgA nephropathy ?

Scope of the IgA Nephropathy Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of IgA nephropathy based on several factors.
• IgA Nephropathy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The IgA nephropathy report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.